Markets:

Overview

News

Currencies

International

Treasuries

iShares U.S. Pharmaceutical ETF (NY:IHE)

102.75 +0.07 (+0.07%)

Streaming Delayed Price Updated: 9:40 AM EDT, Sep 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Pharmaceutical ETF

< Previous 1 2 3 Next >

Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund? ↗

September 08, 2026

IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.

Via The Motley Fool

Topics ETFs

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026? ↗

September 08, 2026

IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.

Via The Motley Fool

Topics ETFs

Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗

August 21, 2026

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

Via The Motley Fool

Topics ETFs

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? ↗

January 30, 2026

Via Stocktwits

Why Did NRXP Stock Surge 21% Pre-Market Today? ↗

January 14, 2026

Via Stocktwits

In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech? ↗

August 20, 2026

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

Via The Motley Fool

Topics ETFs

IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy? ↗

August 20, 2026

XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield.

Via The Motley Fool

Topics ETFs

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? ↗

August 14, 2026

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

Via The Motley Fool

Topics ETFs

XLV vs. IHE: Which Healthcare ETF Is the Better Buy? ↗

July 31, 2026

IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.

Via The Motley Fool

Topics ETFs Intellectual Property

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? ↗

July 22, 2026

IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost.

Via The Motley Fool

Topics ETFs

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗

July 19, 2026

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

Via The Motley Fool

Topics ETFs

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? ↗

July 18, 2026

IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?

Via The Motley Fool

Topics ETFs

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗

July 16, 2026

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Via The Motley Fool

Topics ETFs

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗

July 10, 2026

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

Via The Motley Fool

Topics ETFs

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗

July 05, 2026

Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs.

Via The Motley Fool

Topics ETFs Intellectual Property

Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗

June 17, 2026

Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability.

Via The Motley Fool

Topics ETFs

iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns ↗

June 10, 2026

One fund channels profits to breast cancer research, while the other focuses on established drugmakers. See how their strategies shape risk and sector exposure.

Via The Motley Fool

Topics ETFs

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. ↗

May 27, 2026

A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.

Via The Motley Fool

Topics ETFs

FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report ↗

March 06, 2026

The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.

Via Stocktwits

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗

March 03, 2026

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

Via Stocktwits

Topics Workforce

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗

February 18, 2026

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

Via Stocktwits

Topics ETFs Government

Why Did IINN Stock Surge 28% In Pre-Market Today? ↗

February 09, 2026

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

Via Stocktwits

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗

February 05, 2026

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

Via Stocktwits

Topics Intellectual Property

LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗

February 04, 2026

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Via Stocktwits

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Via Stocktwits

Topics World Trade

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗

November 15, 2025

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.

Via Benzinga

Topics ETFs

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Via Benzinga

Topics Government World Trade

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.